Small Steps Forward: Adjunctive Therapy for T1D

Overview

Journal J Diabetes

Specialty Endocrinology

Date 2022 Oct 7

PMID 36205524

Authors

Zachary Bloomgarden

Desmond Schatz

Affiliations

Soon will be listed here.

Citing Articles

Mesenchymal Stem Cell Transplantation in Type 1 Diabetes Treatment: Current Advances and Future Opportunity.

Liu J, Wan X, Zheng S, Khan M, He H, Feng Y Curr Stem Cell Res Ther. 2023; 19(9):1175-1184.

PMID: 37817652 DOI: 10.2174/011574888X268740231002054459.

References

de Vries M, Westerink J, Kaasjager K, de Valk H . Prevalence of Nonalcoholic Fatty Liver Disease (NAFLD) in Patients With Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis. J Clin Endocrinol Metab. 2020; 105(12). PMC: 7526735. DOI: 10.1210/clinem/dgaa575. View

Garg S, Henry R, Banks P, Buse J, Davies M, Fulcher G . Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes. N Engl J Med. 2017; 377(24):2337-2348. DOI: 10.1056/NEJMoa1708337. View

Williams K, Erbey J, Becker D, Arslanian S, Orchard T . Can clinical factors estimate insulin resistance in type 1 diabetes?. Diabetes. 2000; 49(4):626-32. DOI: 10.2337/diabetes.49.4.626. View

Garofolo M, Gualdani E, Scarale M, Bianchi C, Aragona M, Campi F . Insulin Resistance and Risk of Major Vascular Events and All-Cause Mortality in Type 1 Diabetes: A 10-Year Follow-up Study. Diabetes Care. 2020; 43(10):e139-e141. PMC: 7510021. DOI: 10.2337/dc20-0433. View

Cree-Green M, Bergman B, Cengiz E, Fox L, Hannon T, Miller K . Metformin Improves Peripheral Insulin Sensitivity in Youth With Type 1 Diabetes. J Clin Endocrinol Metab. 2019; 104(8):3265-3278. PMC: 6584133. DOI: 10.1210/jc.2019-00129. View

Singh A, Le P, Lopez R, Alkhouri N . The utility of noninvasive scores in assessing the prevalence of nonalcoholic fatty liver disease and advanced fibrosis in type 1 diabetic patients. Hepatol Int. 2018; 12(1):37-43. DOI: 10.1007/s12072-017-9840-z. View

Peters A, Buschur E, Buse J, Cohan P, Diner J, Hirsch I . Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium-Glucose Cotransporter 2 Inhibition. Diabetes Care. 2015; 38(9):1687-93. PMC: 4542270. DOI: 10.2337/dc15-0843. View

Rosenstock J, Marquard J, Laffel L, Neubacher D, Kaspers S, Cherney D . Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials. Diabetes Care. 2018; 41(12):2560-2569. DOI: 10.2337/dc18-1749. View

Musso G, Sircana A, Saba F, Cassader M, Gambino R . Assessing the risk of ketoacidosis due to sodium-glucose cotransporter (SGLT)-2 inhibitors in patients with type 1 diabetes: A meta-analysis and meta-regression. PLoS Med. 2020; 17(12):e1003461. PMC: 7771708. DOI: 10.1371/journal.pmed.1003461. View

10.

Seckold R, Howley P, King B, Bell K, Smith A, Smart C . Dietary intake and eating patterns of young children with type 1 diabetes achieving glycemic targets. BMJ Open Diabetes Res Care. 2019; 7(1):e000663. PMC: 6606069. DOI: 10.1136/bmjdrc-2019-000663. View

11.

Purnell J, Zinman B, Brunzell J . The effect of excess weight gain with intensive diabetes mellitus treatment on cardiovascular disease risk factors and atherosclerosis in type 1 diabetes mellitus: results from the Diabetes Control and Complications Trial/Epidemiology of Diabetes.... Circulation. 2012; 127(2):180-7. PMC: 3819101. DOI: 10.1161/CIRCULATIONAHA.111.077487. View

12.

Strowig S, Raskin P . The effect of rosiglitazone on overweight subjects with type 1 diabetes. Diabetes Care. 2005; 28(7):1562-7. DOI: 10.2337/diacare.28.7.1562. View

13.

Rawshani A, Rawshani A, Franzen S, Eliasson B, Svensson A, Miftaraj M . Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes. N Engl J Med. 2017; 376(15):1407-1418. DOI: 10.1056/NEJMoa1608664. View

14.

de Vries M, El-Morabit F, van Erpecum K, Westerink J, Bac S, Kaasjager H . Non-alcoholic fatty liver disease: identical etiologic factors in patients with type 1 and type 2 diabetes. Eur J Intern Med. 2022; 100:77-82. DOI: 10.1016/j.ejim.2022.03.025. View

15.

Mathieu C, Dandona P, Gillard P, Senior P, Hasslacher C, Araki E . Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial. Diabetes Care. 2018; 41(9):1938-1946. DOI: 10.2337/dc18-0623. View

16.

Garg S, Ritchie P, Moser E, Snell-Bergeon J, Freson B, Hazenfield R . Effects of colesevelam on LDL-C, A1c and GLP-1 levels in patients with type 1 diabetes: a pilot randomized double-blind trial. Diabetes Obes Metab. 2011; 13(2):137-43. DOI: 10.1111/j.1463-1326.2010.01320.x. View

17.

Libman I, Miller K, DiMeglio L, Bethin K, Katz M, Shah A . Effect of Metformin Added to Insulin on Glycemic Control Among Overweight/Obese Adolescents With Type 1 Diabetes: A Randomized Clinical Trial. JAMA. 2015; 314(21):2241-50. DOI: 10.1001/jama.2015.16174. View

18.

Conway B, Miller R, Costacou T, Fried L, Kelsey S, Evans R . Temporal patterns in overweight and obesity in Type 1 diabetes. Diabet Med. 2010; 27(4):398-404. PMC: 3129711. DOI: 10.1111/j.1464-5491.2010.02956.x. View

19.

Bohn B, Herbst A, Pfeifer M, Krakow D, Zimny S, Kopp F . Impact of Physical Activity on Glycemic Control and Prevalence of Cardiovascular Risk Factors in Adults With Type 1 Diabetes: A Cross-sectional Multicenter Study of 18,028 Patients. Diabetes Care. 2015; 38(8):1536-43. DOI: 10.2337/dc15-0030. View

20.

Garg S, Moser E, Bode B, Klaff L, Hiatt W, Beatson C . Effect of sitagliptin on post-prandial glucagon and GLP-1 levels in patients with type 1 diabetes: investigator-initiated, double-blind, randomized, placebo-controlled trial. Endocr Pract. 2012; 19(1):19-28. DOI: 10.4158/EP12100.OR. View